Roche c501/e411 Autoanalyzer for CTSA Core Resources at Penn and CHOP

Roche c501/e411 自动分析仪适用于 Penn 和 CHOP 的 CTSA 核心资源

• 批准号: 7793675
• 负责人: Muredach P Reilly
• 金额: $ 22.75万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-04-22 至 2011-04-21
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7793675
• 关键词: Adult; Aging; Applications Grants; Award; Biochemical; Biological Assay; Biomedical Research; Calendar; Childhood; Clinical; Clinical Pathology; Clinical Trials; Communities; Ensure; Epidemiologic Studies; Funding; Goals; Health Services Research; Home environment; Institutes; Investments; Laboratories; Methodology; Mission; Pediatric Hospitals; Pennsylvania; Philadelphia; Process; Reagent; Research; Research Personnel; Resources; Sampling; Services; Therapeutic; Translational Research; United States National Institutes of Health; Universities; cost; instrumentation; meetings; translational medicine

DESCRIPTION (provided by applicant): Clinical and translational science is a major focus for the University of Pennsylvania (Penn) and Children's' Hospital of Philadelphia (CHOP). Indeed, the Penn/CHOP CTSA has catalyzed major institutional investments in translational research through the Institute of Translational Medicine and Therapeutics (ITMAT), the academic home of the CTSA. A major transformational mission of ITMAT/CTSA is to provide cost-effective and efficient services for research sample processing, storage, and assaying through the Translational Core Laboratories (TCL). A key TCL service has been autoanalyzers exclusively focused on research needs that cannot be met by Clinical Pathology including batch analysis of small sample volumes and optimal multiplexing. The TCL has used a Roche Hitachi 912 autoanalyzer for research-focused biochemical analyses - however, the Hitachi 912 is now an aging platform and will not be supported by Roche after the end of this calendar year. In this Shared Instrumentation Grant proposal, we seek to replace this platform with a Roche Cobas c501/e411 biochemical/immunochemical autoananlyzer. This analyzer will (a) increase capacity while using similar reagents (thus ensuring continuity for ongoing projects), (b) extend analyzer services to include a much broader array of multiplexing options which is critical to this research community (limited sample resources is the norm), and (c) meet an increasing demand for these service. We present five major users projects to illustrate the unique importance and reach of these services to clinical and translational research across Penn/CHOP and beyond - projects span pediatric to adult research, K-23 to U01 awards, and include mechanistic clinical trials, community translational research, and epidemiological studies. We emphasize, however, that this analyzer will be used by over 40 NIH-funded investigators for specialized research applications that cannot appropriately be met by Clinical Pathology or by alternative methodologies. Provision of research oriented, high-quality, accessible and cost-effective autoanalyzer services is critical to the biomedical research goals of Penn/CHOP and their CTSA-related partners as well as to the larger NIH mission to enhance clinical and translational research nationally.

描述（由申请人提供）：临床和转化科学是宾夕法尼亚大学（Penn）和费城儿童医院（CHOP）的重点。的确，Penn/Chop CTSA通过CTSA的学术住所转化医学和治疗学研究所（ITMAT）催化了转化研究中的重大机构投资。 ITMAT/CTSA的主要变革任务是通过转化核心实验室（TCL）为研究样本处理，存储和测定提供具有成本效益和高效的服务。一项关键的TCL服务是自动分析仪仅专注于研究需求，而临床病理无法满足的研究需求，包括对小样品量和最佳多路复用的批处理分析。 TCL使用了Roche Hitachi 912自动分析仪进行研究以研究为重点的生化分析 - 但是，日立912现在是一个老化的平台，在本日历年结束后，Roche不会支持Roche。在这个共享的仪器赠款提案中，我们试图用Roche Cobas C501/E411生化/免疫化学自动化自动瓦纳利策替换该平台。该分析仪将（a）在使用类似的试剂（从而确保正在进行的项目的连续性）的同时（a）扩大分析仪服务以包括对本研究社区至关重要的多种多路复用选项（有限的样本资源是常态），并且（c）满足对这些服务的需求不断提高。我们提出了五个主要用户项目，以说明这些服务对宾夕法尼亚/CHOP及其他地区的临床和转化研究的独特重要性和影响 - 项目涵盖小儿研究到成人研究，K -23至U01奖项，并包括机械临床试验，社区转化研究和流行病学研究。但是，我们强调的是，该分析仪将被40多名NIH资助的研究人员用于专门研究应用程序，这些应用程序无法通过临床病理或替代方法适当地满足。提供以研究为导向，高质量，可访问和具有成本效益的自动分析仪服务对Penn/Chop及其与CTSA相关的合作伙伴的生物医学研究目标以及对增强全国临床和翻译研究的更大的NIH使命至关重要。